<DOC>
	<DOCNO>NCT00503971</DOCNO>
	<brief_summary>This open label , non-randomized , sequential , phase I/II trial patient stage IIIB IV non-small cell lung cancer ( NSCLC ) EGFR mutation progression Erlotinib . The study two part . The first part ( phase I ) dose find ( MTD ) study implement three hospital . The second part study ( phase II ) asses safety efficacy combination . In second part ( phase II ) patient treated oral Erlotinib 150 mg P.O daily plus oral Vorinostat administer accord result phase I . The study endpoint evaluate include safety response rate ( RR ) primary endpoint clinical benefit rate ( CBR ) , time progression , time response , response duration progression free survival secondary endpoint . All patient ( phase I II ) treat progression disease , unacceptable toxicity withdrawal consent , treat discretion principal investigator .</brief_summary>
	<brief_title>Phase I/II Oral Vorinostat Combination With Erlotinib NSCLC Patients With EGFR Mutations With DP After Erlotinib .</brief_title>
	<detailed_description>SAMPLE : Patients must histologically-confirmed diagnosis stage IIIB IV NSCLC , prior treatment Erlotinib . In phase I study upper expect number patient eighteen . In phase II thirty two eligible patient include study . The enrollment period approximately 1.5 year . All patient treat Erlotinib Vorinostat regimen . Participating hospital Spanish Lung Cancer Group ( SLCG ) . For phase I portion , 3 site : Dr. Noemi Reguart Dr. Rafael Rosell , Institut Catala d'Oncologia , Hospital Germans Trias Pujol , Badalona ( Barcelona , Spain ) , Dr. Felip Cardenal , Institut Catalan d'Oncologia . Centre Sanitari Universitari de Bellvitge ( CSUB ) , Hospitalet de Llobregat ( Barcelona , Spain ) Dr. Lola Isla , Hospital Clinico Lozano Blesa , ( Zaragoza , Spain ) For phase II portion , 10 hospital ( add 7 first 3 ) Spanish Lung Cancer Group ( SLCG ) involve . Hospitals include phase I study . OBJECTIVES AND HYPOTHESES Primary Phase I ( 1 ) To determine MTD oral vorinostat combination erlotinib ensure treatment sufficiently safe tolerable permit study . Phase II ( 1 ) To determine percentage patient free progression 12 week . Hypothesis : We consider treatment effective obtain percentage patient free progression 12 week high 60 % . Secondary ( 1 ) To determine CBR ( clinical benefit rate ) , response rate , time progression , time response , response duration , progression free survival patient treat vorinostat erlotinib combination . Hypothesis : CBR least 25 % include stable disease least 3 month objective RECIST response least 4 week . Exploratory endpoint Molecular analysis : Main Objective : analysis EGFR mutation ( exon 19 , 20 21 ) serum sample baseline ( treatment ) , three month treatment end treatment . Secondary Objectives : retrospective analysis molecular marker potentially related drug sensitivity E-catherin protein expression , thioredoxin serum level ; Hsp70 ; methylation 14-3-3r CHFR .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histologically confirm NSCLC 2 . Diagnosis advance stage IIIB pleural effusion IV NSCLC 3 . Previous disease progression &gt; = 3 month treatment Erlotinib . Must tolerate erlotinib dose 150 mg daily prior month . 4 . Have demonstrate mutation epidermal growth factor receptor ( EGFR ) Exon 19 Exon 21 ( Exon 19 mutation characterize inframe deletion ( 747750 ) , Exon 21 mutation result L858R substitution ) . 5 . At least 18 year old . 6 . Measurable disease define presence least one lesion accurately measure least one dimension use RECIST guideline . 7 . At least 4 week prior major surgery radiation therapy adequately recover toxicity and/or complication 8 . ECOG performance status 0 2 9 . Adequate bone marrow function without current use colony stimulate factor . 10 . Adequate coagulation function . 11 . Adequate liver function 12 . Adequate renal function 13 . Nonsterilized premenopausal female , pregnancy test must perform patient must agree use barrier method contraception . Male patient must agree use adequate method contraception . 14 . Available periodic blood sample analysis , study relate assessment 15.Patient ability understand willingness sign inform consent form . 16.Patient able read , understand , complete study questionnaire . 1 . Patient treat investigational agent indication within 4 week study treatment . 2 . Patient previously treat Vorinostat HDAC inhibitor indication previous 30 day . 3 . Patient history hypersensitivity intolerance Erlotinib . 4 . Patient active infection receive intravenous antibiotic , antiviral antifungal medication 2 week 5 . Patient symptomatic central nervous system metastasis without corticosteroid treatment . 6 . Inability take and/or tolerate oral medication . 7 . Patient know active hepatitis B C infection , ( HIV ) HIVrelated malignancy . 8 . Pregnant breastfeeding . 9 . Patient history gastrointestinal disease , surgery 10 . Patient uncontrolled undercurrent illness circumstance could limit compliance study . 11 . History malignancy except inactive nonmelanoma skin cancer and/or situ carcinoma cervix , solid tumor treat curatively without evidence recurrence least 5 year prior study enrollment . 12 . Patient prescription nonprescription drug product know influence CYP3A4 discontinue prior day 1 dosing withheld throughout study 2 week last dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Vorinostat</keyword>
	<keyword>NSCLC</keyword>
	<keyword>EGFR</keyword>
	<keyword>Erlotinib</keyword>
</DOC>